Tirzepatide activates the GIP and GLP-1 receptors. Researchers call it a dual agonist because a single molecule can activate both targets. Early scientific papers use the development code LY3298176. Receptor studies examine how the molecule interacts with these targets under controlled laboratory conditions.
What does each receptor name mean?
GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both are hormones involved in the body’s response to nutrients. Researchers can use a cell assay to measure what happens when a test molecule activates either receptor.
What is biased agonism?
A receptor can signal through more than one pathway. In laboratory studies, scientists observed that tirzepatide favored some downstream signals over others at the GLP-1 receptor under the conditions studied. This is called signaling bias. It describes what a particular experiment measured, including the assay conditions and the molecule used as a reference.
Why do researchers describe it as imbalanced?
The term refers to how tirzepatide’s activity at the two receptors compares with that of the corresponding natural hormones in specific assays. It does not establish a fixed ratio of receptor activity in a person. Different cell systems, exposure levels or endpoints can change the comparison.
How does the mechanism relate to clinical results?
Mechanism studies help explain how an effect might arise. Randomized trials measure outcomes and adverse events in participants. The two types of evidence complement each other. A laboratory difference in receptor signaling cannot by itself predict the size of a clinical benefit, compare approved products, or establish an individual response.
Sources and further reading
Original tirzepatide receptor pharmacology study · U.S. Zepbound prescribing information · SURMOUNT-1 randomized trial